MX2020012292A - Compuestos para el tratamiento de cáncer de pancreas. - Google Patents

Compuestos para el tratamiento de cáncer de pancreas.

Info

Publication number
MX2020012292A
MX2020012292A MX2020012292A MX2020012292A MX2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A MX 2020012292 A MX2020012292 A MX 2020012292A
Authority
MX
Mexico
Prior art keywords
pancreatic cancer
compounds
treatment
formula
therapeutically effective
Prior art date
Application number
MX2020012292A
Other languages
English (en)
Inventor
Wei Li
Miller Duane D
Wang Qinghui
Subhash Chauhan
Vivek Kumar Kashyap
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of MX2020012292A publication Critical patent/MX2020012292A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

La presente invención abarca métodos para tratar el cáncer de páncreas mediante el uso de cantidades terapéuticamente efectivas de compuestos representados por la estructura de fórmula (I).
MX2020012292A 2018-05-15 2019-05-15 Compuestos para el tratamiento de cáncer de pancreas. MX2020012292A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671833P 2018-05-15 2018-05-15
PCT/US2019/032476 WO2019222392A1 (en) 2018-05-15 2019-05-15 Compounds for treatment of pancreatic cancer

Publications (1)

Publication Number Publication Date
MX2020012292A true MX2020012292A (es) 2021-03-29

Family

ID=68541005

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012292A MX2020012292A (es) 2018-05-15 2019-05-15 Compuestos para el tratamiento de cáncer de pancreas.

Country Status (9)

Country Link
US (1) US20190374512A1 (es)
EP (1) EP3793548A4 (es)
JP (1) JP2021523915A (es)
KR (1) KR20210021982A (es)
CN (1) CN112437664A (es)
AU (1) AU2019270091A1 (es)
CA (1) CA3099922A1 (es)
MX (1) MX2020012292A (es)
WO (1) WO2019222392A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512816A (ja) * 2021-04-05 2024-03-19 ヴェル インコーポレイテッド 炎症を治療する方法
WO2023212252A1 (en) * 2022-04-28 2023-11-02 Veru Inc. Polymorphs of [2-(1h-indol-3-yl)-1h-imidazol-4-yl](3,4,5- trimethoxy)methanone and its salts

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US8822513B2 (en) * 2010-03-01 2014-09-02 Gtx, Inc. Compounds for treatment of cancer
MX2010014066A (es) * 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
US9029408B2 (en) * 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
WO2011109059A1 (en) * 2010-03-01 2011-09-09 Gtx, Inc. Compounds for treatment of cancer
KR101806255B1 (ko) * 2010-08-24 2017-12-07 지티엑스, 인코포레이티드 암 치료용 화합물
WO2014138279A1 (en) * 2013-03-05 2014-09-12 University Of Tennessee Research Foundation Compounds for treatment of cancer

Also Published As

Publication number Publication date
AU2019270091A1 (en) 2020-12-24
CA3099922A1 (en) 2019-11-21
JP2021523915A (ja) 2021-09-09
EP3793548A4 (en) 2022-03-09
CN112437664A (zh) 2021-03-02
WO2019222392A1 (en) 2019-11-21
KR20210021982A (ko) 2021-03-02
EP3793548A1 (en) 2021-03-24
US20190374512A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
ZA201906111B (en) Cyclic di-nucleotides compounds for the treatment of cancer
MX2022005827A (es) Derivados de pirazol como inhibidores de malt1.
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
MX2017012730A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido) para el tratamiento de cancer.
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2020012291A (es) Compuestos para el tratamiento de cancer de mama triple negativo y cancer de ovario.
PH12018500268A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
MX2020011234A (es) Moduladores de receptor similar al dominio de oligomerizacion de union a nucleotidos que contiene dominio de pirina 3 (nlrp3).
PH12017501879A1 (en) Methods for treating cancer
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
NZ761519A (en) Nlrp3 modulators
EA202090414A1 (ru) Соединения и их применение
NZ759764A (en) Glucuronide prodrugs of janus kinase inhibitors
MX2020012281A (es) Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas.
MX2016016507A (es) Composiciones y metodos para tratar canceres.
EA201690763A1 (ru) Лечение рака поджелудочной железы
MX2020012292A (es) Compuestos para el tratamiento de cáncer de pancreas.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
MX2019000542A (es) Derivados de pirazolilaminobenzimidazol como inhibidores de jak.
IL289201A (en) Compounds for the treatment of cancer